A randomised comparison of ganirelix and cetrorelix use in ICSI cycle of women with polycystic ovary syndrome
MetadataShow full item record
CitationKars, B., Sofuoğlu, K., Çalışkan, E., Öztekin, D. C., Aktaş, R. G. ve Tuğ, N. (2007). A randomised comparison of ganirelix and cetrorelix use in ICSI cycle of women with polycystic ovary syndrome. Fertility and Sterility, Elsevier. 88, s. 181.
OBJECTIVE: To compare the ICSI outcome of two multidose gonadotropin releasing hormone antagonist (GnRH-ant) in women with polycystic ovary syndrome (PCOS). DESIGN: A prospective, randomized, single-blind study in a referral center for assisted reproduction. MATERIALS AND METHODS: Eighty two women with the diagnosis of PCOS were randomly assigned to either multidose ganirelix or multidose cetrorelix, started when the dominant follicle has reached >13 mm in diameter. The sample size calculation was based on an average of 36% clinical pregnancy rate. To find a 16% change in the clinical pregnancy rate with a power of 0.80 at a ¼ 0.05, the total sample size required was 71 women. In order to achieve adequate sample size after cycle cancellation 82 women were recruited in the study. Chi-square and student-t test were used as appropriate. RESULTS: The mean age, the body mass index, infertility period, cleavage rate, fertilisation rates were similar in the two groups (P>0.05). The cycle cancellation rate was 14.6% in the ganirelix group and 12.2% in the cetrorelix group (P¼0.07). The number of good quality embryos obtained was 2.8 0.6 in the ganirelix group while it was 2.6 0.5 in the cetrorelix group. The clinical pregnancy rate was 40% in the ganirelix group and 30.6% in the cetrorelix group (P¼0.4). Take home baby rate were 31.4% in the ganirelix group and 22.2% in the cetrorelix group (P¼0.38). CONCLUSIONS: The two GnRH-ant were found to have similar ICSI outcomes in PCOS patients.
SourceFertility and Sterility
- Makale Koleksiyonu 
The following license files are associated with this item: